Announcements Trials
Browse Landscape

Phase

Phase 2 23Phase 3 19Phase 1/2 7Phase 1 6Phase 2/3 3Phase EARLY_PHASE1 1Phase 4 1

Status

Recruiting 3Active not recruiting 3Not yet recruiting 1

Sponsor Class

INDUSTRY 4OTHER 2NIH 1

Study Type

Interventional 7

Sponsor

Cancer Type

Lymphoid 5Other hematologic neoplasm 3

Conditions

Lymphoma, Large B-Cell, Diffuse 3Recurrence 2Lymphoma, Follicular 2Leukemia, Lymphocytic, Chronic, B-Cell 2Lymphoma, Non-Hodgkin 1Lymphoma, B-Cell, Marginal Zone 1Leukemia, Hairy Cell 1

Interventions

pembrolizumab 31Carboplatin 24Specimen Handling 19Magnetic Resonance Spectroscopy 17Cyclophosphamide 17Nivolumab 14Dexamethasone 14Bevacizumab 13fludarabine 12atezolizumab 11Temozolomide 11Gemcitabine 11Biopsy 11Paclitaxel 10venetoclax 9Pemetrexed 9Ipilimumab 9Cisplatin 8Rituximab 7Prednisone 7Oxaliplatin 7Lenalidomide 7Fluorouracil 7Docetaxel 7Capecitabine 7olaparib 6Vincristine 6Leucovorin 6patritumab deruxtecan 5lenvatinib 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

7 trials
RecentStart dateEnrollment
Phase 1/2 × Rituximab × 30 days × Clear all
NCT05533775 2026-06-03

iMATRIX GLO

Hoffmann-La Roche

Phase 1/2 Recruiting
65 enrolled

Recurrence

NCT06965114 2026-06-03

Testing the Combination of Anti-cancer Drugs, Tovorafenib Plus Rituximab, in Patients With Hairy Cell Leukemia

National Cancer Institute (NCI)

Phase 1/2 Recruiting
84 enrolled
Other hematologic neoplasm

Leukemia, Hairy Cell

NCT04542824 2026-06-02

EPCOREâ„¢ NHL-3

Genmab

Phase 1/2 Active not recruiting
78 enrolled
LymphoidOther hematologic neoplasm

Lymphoma, Follicular, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone

NCT04623541 2026-06-02

EPCOREâ„¢ CLL-1

Genmab

Phase 1/2 Active not recruiting
194 enrolled
LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell

NCT04663347 2026-06-02

EPCOREâ„¢ NHL-2

Genmab

Phase 1/2 Active not recruiting
543 enrolled
Lymphoid

Lymphoma, Follicular, Lymphoma, Large B-Cell, Diffuse

NCT06040320 2026-05-27

Polatuzumab Vedotin (Pola) Plus Rituximab (R) in Patients With Post-transplant Lymphoproliferative Disorder (PTLD)

Washington University School of Medicine

Phase 1/2 Recruiting
12 enrolled
Lymphoid

Lymphoma, Non-Hodgkin

NCT07601607 2026-05-22

Lisaftoclax Plus Chidamide and Rituximab in Relapsed or Refractory Diffuse Large B-cell Lymphoma

Sun Yat-sen University

Phase 1/2 Not yet recruiting
51 enrolled
Lymphoid

Recurrence, Lymphoma, Large B-Cell, Diffuse

Data powered by HemOnc (CC BY 4.0) Colophon âš¡